A Pilot Trial of Jawarish Amla as Adjuvant to Anti-Tubercular Treatment Drugs for Control of Adverse Reactions in DOTS Regime in Pulmonary TB Patients

Arish Mohammad Khan Sherwani, Muhammad Zulkifle, Rehmatulla Mohammad Saleha


DOI: http://dx.doi.org/10.5915/44-1-9988

Background and objectives: One of the greatest challenges of health care systems at the dawn of the 21st century is tuberculosis (TB). Drug resistant strains of TB are becoming a global public health risk. These strains commonly appear due to faulty therapies. Patients frequently stop treatment due to the toxicity of anti-tubercular treatment (ATT) drugs. Amla (Emblica officinalis) is a well-known Unani single drug. Jawarish amla is a Unani compound formulation which is commonly used to administer amla. This study tested the efficacy of jawarish amla as an adjuvant to ATT drugs in reducing their side effects.

Methodology: Half of forty eligible pulmonary tuberculosis patients were randomly assigned to Test (Group B) and the other half to Control (Group A). Six grams of jawarish amla twice daily was administered to the test group, and the same dosage of placebo was administered to control group along with directly observed treatment, short course chemotherapy (DOTS) for 60 days. Fisher exact test and paired t-test were applied for efficacy evaluation. Grading of symptoms was done to assess the toxicity of ATT and outcome of the adjuvant.

Results and discussion: Significant improvements were observed in almost all subjective and objective parameters. The exceptions were serum creatine and serum uric acid, which showed non-significant slight elevations within normal limits.

Conclusion: Jawarish amla was ascertained to be safe and effective adjuvant of DOTS in combating the adverse effects of ATT drugs.


Pulmonary Tuberculosis; Side Effects; Drug Resistance; Herbal Medicine; Adverse Reaction; Jawarish Amla

Full Text:


DOI: https://doi.org/10.5915/44-1-9988

Islamic Medical Association of North America (IMANA) | JIMA and IMANA on Twitter


Creative Commons License
This work by Work's author(s) is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.